title: Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase.
authors.forename: Jaideep
authors.initials: J
authors.lastname: Gogtay
authors.forename: Siddharth
authors.initials: S
authors.lastname: Chahchad
authors.forename: Sonali
authors.initials: S
authors.lastname: Jadhav
authors.forename: Shrinivas
authors.initials: S
authors.lastname: Purandare
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016568:Drugs, Generic / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016568:Drugs, Generic; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate